Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period
MRK outlines solid long-term outlook with more than $70B opportunity beyond Keytruda LOE, backed by pipeline progress, new product launches and M&A deals.
Zacks·2d ago
More News
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.
Zacks·2d ago
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
Zacks·5d ago
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
Zacks·6d ago
International ETFs to Watch as Foreign Stock Markets Beat the US
International stocks crushed U.S. markets in 2025, with ETFs such as SPDW and JIVE emerging as top plays on the global shift.
Zacks·8d ago
Here's What Will Drive AbbVie's Top-line Growth in 2026
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.
Zacks·8d ago
BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
Zacks·12d ago
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View
ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong 2026 EPS guidance.
Zacks·13d ago
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, reshaping its growth mix.
Zacks·14d ago
Buy AbbVie Stock Before Q4 Earnings? Here's What to Know
ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.